Retatrutide is an experimental “triple agonist” (acting on GLP-1, GIP, and glucagon receptors) that could outperform current GLP-1 and dual-agonist medications. Early trials show historic weight loss of up to 24 ÷ of body weight at 48 weeks, alongside massive improvements in blood sugar and liver health.
A new class of weight-loss medication is attracting significant attention in the medical community. Retatrutide, developed by Eli Lilly, has produced weight loss numbers in clinical trials that surpass anything seen before in obesity pharmacotherapy. For patients currently on semaglutide or tirzepatide, the natural question is whether this new drug will render those treatments obsolete.
At Harmonia Health Solutions, our team closely follows the evolving research in weight loss medicine to help our patients stay informed and make the best decisions for their health. If you’re curious about what retatrutide means for your long-term treatment path, schedule a free consultation with one of our licensed providers today.
Retatrutide is a triple hormone receptor agonist, meaning it activates three separate biological pathways at once: GLP-1, GIP, and glucagon. Current approved medications target one or two of these pathways. That added layer of hormonal engagement is what makes retatrutide structurally distinct and, based on early data, more metabolically potent.
Understanding why this difference matters requires a brief look at how each generation of these medications works.
Semaglutide, the active ingredient in Wegovy and Ozempic, is a GLP-1 receptor agonist. It mimics a gut hormone your body releases after eating, which signals fullness to the brain, slows gastric emptying, and helps regulate insulin.
In the landmark STEP 1 trial published in the New England Journal of Medicine, semaglutide at 2.4 mg produced an average weight loss of approximately 14.9 percent over 68 weeks (treatment-regimen estimand), compared to 2.4 percent with placebo.
Tirzepatide, the active ingredient in Mounjaro and Zepbound, is a dual GIP and GLP-1 receptor agonist. By activating both pathways simultaneously, it enhances insulin secretion, improves fat metabolism, and amplifies satiety signals beyond what a GLP-1 agonist alone can produce.
In the SURMOUNT-1 trial, tirzepatide at its highest dose (15 mg) produced an average weight loss of 20.9 percent (treatment-regimen estimand) to 22.5 percent (efficacy estimand) over 72 weeks.
Retatrutide adds a third layer: glucagon receptor activation. Glucagon is a hormone traditionally known for raising blood sugar, but when combined with GLP-1 and GIP agonism, its effects shift. Research published in PMC shows this triple action increases energy expenditure, promotes fat oxidation, reduces liver fat, and may enhance lipolysis in adipose tissue.
Patients taking retatrutide are not only eating less; their metabolism is also being pushed to burn stored fat.
The Phase 2 and Phase 3 trial data for retatrutide is striking. Across both Phase 2 and Phase 3 studies, participants achieved weight loss percentages that exceeded anything previously recorded for a pharmacological obesity treatment, though these trials compared retatrutide to a placebo, not directly to semaglutide or tirzepatide.
Here is what the published and reported data show:
A Phase 2, double-blind, randomized, placebo-controlled trial published in the New England Journal of Medicine in June 2023 enrolled adults with a BMI of 30 or higher (or 27 or higher with a weight-related condition). Participants taking retatrutide at the 12 mg dose lost an average of 24.2 percent of their body weight at 48 weeks, compared to 2.1 percent in the placebo group.
A systematic review and meta-analysis published in PMC, covering 878 patients across three randomized controlled trials, found retatrutide significantly reduced body weight, BMI, waist circumference, and fasting plasma glucose.
In December 2025, Eli Lilly announced positive topline results from the Phase 3 TRIUMPH-4 trial, a 68-week, randomized, double-blind, placebo-controlled study involving 445 adults with obesity or overweight and knee osteoarthritis. Participants on the 12 mg dose achieved an average weight loss of 28.7 percent, while those on the 9 mg dose lost 26.4 percent.
Among patients who remained on the 12 mg dose throughout the trial, 58.6 percent achieved at least 25 percent weight loss, and 39.4 percent achieved at least 30 percent. These results, reported by Eli Lilly, represent the highest efficacy recorded to date in a Phase 3 obesity trial.
When looking across separate trials with different populations and study designs, the general weight loss trajectory runs approximately 14.9 percent for semaglutide (STEP 1, treatment-regimen estimand at 68 weeks), 20.9 to 22.5 percent for tirzepatide (SURMOUNT-1 at 72 weeks, depending on the estimand) and 24.2 to 28.7 percent for retatrutide across Phase 2 and Phase 3, respectively.
To be precise: no head-to-head trial comparing all three medications has been completed, though a dedicated study (TRIUMPH-5, NCT06662383) is expected to directly compare retatrutide and tirzepatide. Numbers from different trials are not perfectly interchangeable, but the directional gap is large enough that researchers and analysts have noted retatrutide’s profile as distinct.
Retatrutide carries a side effect profile similar to other incretin-based therapies, with gastrointestinal symptoms being the most common. Phase 3 data introduced a new safety signal not seen in Phase 2 that warrants attention: a condition called “dysesthesia,” or abnormal sensations of touch.
Patients considering this medication should understand both the familiar and the emerging safety considerations.
In the TRIUMPH-4 trial, the most common adverse events were nausea (43.2 percent at 12 mg, compared to 10.7 percent with placebo), diarrhea (33.1 percent), constipation (25.0 percent), and vomiting (20.9 percent). These rates are consistent with what patients experience on other GLP-1 and GIP therapies during the dose escalation phase. Most GI symptoms tend to diminish as the body adjusts to the medication.
Dysesthesia, an abnormal or unpleasant sense of touch where normal sensations feel unusual or painful, was reported in 20.9 percent of participants on the 12 mg dose and 8.8 percent on the 9 mg dose compared to just 0.7 percent with the placebo.
This signal was not observed in Phase 2 trials and was not anticipated by analysts ahead of the TRIUMPH-4 readout. While Eli Lilly noted most cases were mild and infrequently led to discontinuation, it remains an area of active monitoring across remaining Phase 3 trials.
Discontinuation rates due to adverse events in TRIUMPH-4 ranged from 12.2 percent at 9 mg to 18.2 percent at 12 mg, compared to 4.0 percent with placebo. Some participants discontinued because they felt they were losing too much weight, a pattern now emerging across high-efficacy obesity trials.
Long-term safety data, cardiovascular outcomes, and data in populations with type 2 diabetes are still being collected through the broader TRIUMPH program, with seven additional Phase 3 trials expected to complete in 2026.
Retatrutide is not positioned to replace current GLP-1 medications in the near term. It remains investigational, has not received FDA approval, and still has several large Phase 3 trials to complete. The more accurate framing is that it may eventually expand the available options for patients who need greater weight loss outcomes than current therapies can provide.
Here is a realistic view of what the timeline and landscape look like:
Eli Lilly has indicated it expects to file a New Drug Application for retatrutide based on TRIUMPH program results. A prescription product is not expected to be available until 2027 at the earliest, depending on the standard 10 to 12-month FDA review period. Several Phase 3 trials for obesity, type 2 diabetes, obstructive sleep apnea, and cardiovascular outcomes are still ongoing.
Until the full data package is filed and reviewed, retatrutide will not be available as a prescribed treatment.
Based on available Phase 3 data, retatrutide appears to deliver the most benefit for patients seeking greater total weight reduction than semaglutide or tirzepatide currently achieve.
The additional glucagon receptor activation also shows promise for patients with metabolic dysfunction-associated steatotic liver disease, where Phase 2 data showed reductions in liver fat. As with all medications in this class, retatrutide is not a standalone solution.
Lifestyle modifications, dietary changes, and clinical oversight remain part of any effective treatment plan.
Semaglutide and tirzepatide remain the most effective FDA-approved pharmacological weight loss options available today.
For many patients, these medications produce meaningful results, and they have well-established safety profiles built over years of real-world use. GLP-1 medications are not the definitive answer to weight loss for every individual, but for patients who qualify, they offer clinically meaningful progress right now, without waiting for a next-generation drug to earn approval.
Retatrutide is one of the most promising developments in obesity medicine in years, and the Phase 3 data is genuinely encouraging. At the same time, it is not yet available, and the full safety picture is still emerging through ongoing trials. The best time to start building a sustainable, medically supervised weight management plan is not when the next drug is approved; it is now.
Our team at Harmonia Health Solutions works with each patient to match the right treatment to their individual health profile, goals, and medical history. Learn more about how our process works, and when you’re ready, book a free consultation with one of our licensed providers to explore your options.
Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before making any changes to your medication or treatment plan. If you are experiencing a medical emergency, call 911 or go to your nearest emergency room.
Retatrutide is an investigational once-weekly injectable drug developed by Eli Lilly that activates three hormone receptors: GLP-1, GIP, and glucagon. Ozempic contains semaglutide, which activates only the GLP-1 receptor. The added GIP and glucagon receptor activation in retatrutide appears to increase energy expenditure and fat oxidation beyond what semaglutide alone can produce.
No. Retatrutide has not received FDA approval as of early 2026. It is currently in Phase 3 clinical trials under Eli Lilly’s TRIUMPH program. Several large trials are expected to report results throughout 2026, with a potential FDA filing and review period that could extend into 2026 or 2027.
In the Phase 2 trial published in the New England Journal of Medicine, participants on the 12 mg dose lost an average of 24.2 percent of their body weight at 48 weeks. In the Phase 3 TRIUMPH-4 trial reported in December 2025, participants on the 12 mg dose lost an average of 28.7 percent over 68 weeks, with 58.6 percent achieving at least 25 percent weight loss.
The most common side effects in Phase 3 trials were gastrointestinal, including nausea (up to 43.2 percent at the 12 mg dose), diarrhea, constipation, and vomiting. A new safety signal called dysesthesia, an abnormal or unpleasant sensation of touch, was also reported in up to 20.9 percent of participants at the 12 mg dose. Most cases were described as mild.
It is unlikely to replace tirzepatide outright. Tirzepatide is a well-established, FDA-approved medication with extensive real-world data. Retatrutide may eventually offer an option for patients who need greater weight loss outcomes, but the two medications will likely serve different patient profiles. A direct head-to-head trial called TRIUMPH-5 is underway and will provide more clarity.
Based on Eli Lilly’s development timeline, a regulatory filing is expected after the TRIUMPH Phase 3 trials is complete, with a possible FDA decision in 2026 to 2027. This timeline depends on when the remaining trial data is submitted and how the review process proceeds. Patients interested in retatrutide should discuss their options with a licensed provider for the most up-to-date information on availability.
Early Phase 2 data in patients with type 2 diabetes showed retatrutide reduced HbA1c by 2.2 percent, with 82 percent of participants reaching HbA1c at or below 6.5 percent. Phase 3 trials specifically evaluating retatrutide in people with type 2 diabetes are still ongoing. Until those results are reviewed and the drug receives regulatory approval, it should not be used outside of a clinical trial setting.
At Harmonia Health Solutions, your privacy and safety are our top priorities. We comply with HIPAA regulations to ensure that your personal information is protected, and our consultations are conducted by licensed healthcare professionals who adhere to the highest medical standards.
You’ll find information about longevity products and alternative health services, as well as news regarding the most recent holistic health and wellness research.
